Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Commerzbank Aktiengesellschaft FI

Commerzbank Aktiengesellschaft FI raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 49.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 601 shares of the biopharmaceutical company’s stock after purchasing an additional 199 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Regeneron Pharmaceuticals were worth $423,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of REGN. Farther Finance Advisors LLC boosted its holdings in Regeneron Pharmaceuticals by 7.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 724 shares of the biopharmaceutical company’s stock valued at $761,000 after purchasing an additional 53 shares during the last quarter. Impax Asset Management Group plc boosted its holdings in Regeneron Pharmaceuticals by 4.6% in the 3rd quarter. Impax Asset Management Group plc now owns 5,643 shares of the biopharmaceutical company’s stock valued at $5,932,000 after purchasing an additional 248 shares during the last quarter. United Advisor Group LLC boosted its holdings in Regeneron Pharmaceuticals by 68.9% in the 3rd quarter. United Advisor Group LLC now owns 549 shares of the biopharmaceutical company’s stock valued at $577,000 after purchasing an additional 224 shares during the last quarter. NorthRock Partners LLC boosted its holdings in Regeneron Pharmaceuticals by 83.5% in the 3rd quarter. NorthRock Partners LLC now owns 422 shares of the biopharmaceutical company’s stock valued at $444,000 after purchasing an additional 192 shares during the last quarter. Finally, Crestwood Advisors Group LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 18.4% in the 3rd quarter. Crestwood Advisors Group LLC now owns 476 shares of the biopharmaceutical company’s stock worth $500,000 after acquiring an additional 74 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently commented on REGN. UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. Robert W. Baird decreased their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a report on Wednesday, February 5th. TD Cowen decreased their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. Oppenheimer decreased their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Finally, Bernstein Bank cut their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Stock Up 1.7 %

Shares of NASDAQ:REGN opened at $687.15 on Thursday. The stock has a market cap of $75.12 billion, a P/E ratio of 17.95, a P/E/G ratio of 2.34 and a beta of 0.08. The firm has a fifty day moving average price of $696.58 and a 200 day moving average price of $857.92. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a 1-year low of $642.00 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $11.86 EPS. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.51%. The ex-dividend date is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.